87 related articles for article (PubMed ID: 9689574)
1. Resistance of HIV to antiretroviral agents. Basic concepts.
Dianzani F; Antonelli G; Turriziani O
J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):19-22. PubMed ID: 9689574
[No Abstract] [Full Text] [Related]
2. Viral resistance: a major challenge in managing HIV disease.
Boucher CA; Reedijk M
J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
[No Abstract] [Full Text] [Related]
3. [New trends in HIV].
Volkert R
Dtsch Med Wochenschr; 1998 Sep; 123(38):A7. PubMed ID: 9787287
[No Abstract] [Full Text] [Related]
4. [Human immunodeficiency virus and antiretroviral therapy resistance].
Quirós E; Torti C; Carosi G
Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
[No Abstract] [Full Text] [Related]
5. Salvage therapy for patients failing their current antiretroviral regimen.
Albrecht MA
AIDS Clin Rev; 2000-2001; ():139-91. PubMed ID: 10999220
[No Abstract] [Full Text] [Related]
6. Zidovudine (Retrovir).
Res Initiat Treat Action; 2000 Mar; 6(1):6-7. PubMed ID: 11708188
[No Abstract] [Full Text] [Related]
7. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
8. [Resistance to nucleoside reverse transcriptase inhibitors].
Leal M; Santamaría JM
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055
[No Abstract] [Full Text] [Related]
9. [Resistance to non-nucleoside reverse transcriptase inhibitors].
Casado JL; López JC; Viciana P
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):30-3. PubMed ID: 11428057
[No Abstract] [Full Text] [Related]
10. [AIDS drug in the correct form].
Schenk M
Dtsch Med Wochenschr; 1998 Sep; 123(36):A9. PubMed ID: 9765604
[No Abstract] [Full Text] [Related]
11. HIV pathogenesis and activation of CD4 cells.
Albrecht H
AIDS Clin Care; 2001 Oct; 13(10):99. PubMed ID: 11590927
[TBL] [Abstract][Full Text] [Related]
12. [Resistance to antiretroviral drugs: a clinical, public health and health policy debate].
Guerra Romero L; Parras Vázquez F
Med Clin (Barc); 2000 Oct; 115(11):428-30. PubMed ID: 11093847
[No Abstract] [Full Text] [Related]
13. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
14. Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
Roberts BD; Pau CP; Weinstock H; Heneine W; Butera ST
AIDS; 2000 Dec; 14(17):2797-8. PubMed ID: 11125904
[No Abstract] [Full Text] [Related]
15. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
16. HIV resistance testing proves its value.
Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356
[TBL] [Abstract][Full Text] [Related]
17. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
18. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
20. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
